Molecular characterization of thyroid toxicity: anchoring gene expression profiles to biochemical and pathologic end points.

Organic iodides have been shown to induce thyroid hypertrophy and increase alterations in colloid in rats, although the mechanism involved in this toxicity is unclear. To evaluate the effect that free iodide has on thyroid toxicity, we exposed rats for 2 weeks by daily gavage to sodium iodide (NaI). To compare the effects of compounds with alternative mechanisms (increased thyroid hormone metabolism and decreased thyroid hormone synthesis, respectively), we also examined phenobarbital (PB) and propylthiouracil (PTU) as model thyroid toxicants. Follicular cell hypertrophy and pale-staining colloid were present in thyroid glands from PB-treated rats, and more severe hypertrophy/colloid changes along with diffuse hyperplasia were present in thyroid glands from PTU-treated rats. In PB-and PTU-treated rats, thyroid-stimulating hormone (TSH) levels were significantly elevated, and both thyroxine and triiodothyronine hormone levels were significantly decreased. PB induced hepatic uridine diphosphate-glucuronyltransferase (UDPGT) activity almost 2-fold, whereas PTU reduced hepatic 5'-deiodinase I (5'-DI) activity to < 10% of control in support of previous reports regarding the mechanism of action of each chemical. NaI also significantly altered liver weights and UDPGT activity but did not affect thyroid hormone levels or thyroid pathology. Thyroid gene expression analyses using Affymetrix U34A GeneChips, a regularized t-test, and Gene Map Annotator and Pathway Profiler demonstrated significant changes in rhodopsin-like G-protein-coupled receptor transcripts from all chemicals tested. NaI demonstrated dose-dependent changes in multiple oxidative stress-related genes, as also determined by principal component and linear regression analyses. Differential transcript profiles, possibly relevant to rodent follicular cell tumor outcomes, were observed in rats exposed to PB and PTU, including genes involved in Wnt signaling and ribosomal protein expression. Key words: excess iodide, gene expression, micro arrays, oxidative stress, phenobarbital, propylthiouracil, thyroid, Wnt signaling. Environ Health Perspect 113:1354-1361 (2005). doi: 10.1289/ehp.7690 available via http://dx.doi.org/[Online 12 May 2005]

**********

Thyroid cancer, a fairly uncommon form of cancer in the human population, has causal links to environmental radiation exposures (Meirmanov et al. 2003). Although there are multiple epidemiology studies that associate radiation exposure with thyroid cancer, there have been no studies to associate human thyroid cancer with environmental chemical exposures (Hard 1998). The human thyroid responds toxicologically to multiple anti-thyroid drugs, including excess iodide, propylthiouracil (PTU), and thionamides, but the progression to cancer after repetitive administration has not been observed (Hard 1998; Hill et al. 1998; Markou et al. 2001). In contrast, multiple antithyroid drugs administered to the rat have demonstrated an increase in thyroid tumors, including PTU, thionamides, and the hepatic enzyme inducer phenobarbital (PB) (Capen 1997; Hurley et al. 1998; McClain et al. 1988). Other xenobiotics, including several organic iodides such as amiodarone and erythrosine, have also been associated with thyroid tumor development in the rat. Many organic iodides alter rat thyroid homeostasis, causing thyroid hypertrophy and alterations in colloid that may potentially lead to thyroid tumors after chronic administration (Capen 1997; Hurley et al. 1998).

The mechanisms by which organic iodides induce thyroid toxicity are varied and may include excess iodide being released into the blood during xenobiotic metabolism, toxicity to the liver that alters thyroid hormone metabolism, and/or direct thyroid toxicity that inhibits the release of thyroid hormones into the circulation (Capen 1997; Hurley et al. 1998). In subchronic toxicology studies it has been difficult to predict whether early changes in thyroid pathology could lead to thyroid cancer in the rat after chronic administration of organic iodides. Excess iodide alone can be toxic to thyroid cells in culture and cause thyroid hypertrophy and changes in colloid in vivo in the rat model (Capen 1997; Vitale et al. 2000). It has also been reported that administration of excess iodide promotes thyroid tumor development in rats initiated with N-bis(2-hydroxypropyl)-nitrosamine (Kanno et al. 1992). However, iodide excess alone has not been sufficient in inducing follicular cell hyperplasia and thyroid tumors in rats but more commonly causes hypothyroidism (Backer and Hollowell 2000; Kanno et al. 1994). This is believed to be due partly to the escape from the Wolff-Chaikoff effect (acute inhibition of iodine organification) that is seen within days of exposure to excess iodide (Wolff and Chaikoff 1948). This escape phenomenon is associated with the down-regulation of the sodium iodide (NaI) symporter (NIS) thereby reducing the amount of inorganic iodine in the thyroid so that thyroxine ([T.sub.4]) and thyroid-stimulating hormone (TSH) secretions are returned to normal physiological levels (Eng et al. 1999).

Chronic elevation of TSH levels has been associated with an increased risk of thyroid tumors in the rat, which may be due, in part, to the high turnover of the circulating thyroid hormone triiodothyronine ([T.sub.3]) in this species compared with the lower [T.sub.3] turnover rate in humans (Capen 1997). Many antithyroid drugs and PB mediate their carcinogenic properties by elevating circulating TSH levels in the rat albeit by different mechanisms (Hood et al. 1999; McClain et al. 1988). Although PTU reduces thyroid hormone production by inhibiting thyroglobulin organification in the thyroid and inhibiting the peripheral conversion of [T.sub.4] to active [T.sub.3], PB reduces circulating [T.sub.4] by increasing its hepatic metabolism and excretion via glucoronidation. Reductions in thyroid hormone ([T.sub.4] and [T.sub.3]) by either mechanism causes an elevation in TSH that is sufficient in causing thyroid tumors in rats after prolonged exposure without any evidence of thyroid DNA damage (McClain 1992). Organic iodides may also increase TSH levels by similar mechanisms; however, it is unknown what contribution iodide excess has in their overall toxicity to the rat thyroid. To this end we have implemented biochemical, pathological, and molecular analyses to characterize the rat thyroid response to three model toxicants: excess iodide by using NaI a noncarcinogen, and the rodent thyroid carcinogens PB and PTU, in a modified 2-week endocrine battery (O'Connor et al. 2002). The goals of this study were to identify dose-dependent gene expression profiles induced by excess iodide in rats, determine whether gene expression profiles could be obtained that correlate with clinical and pathological end points in rats, and determine whether profiles are predictive of the carcinogenic potential of each chemical in rats.

Materials and Methods

In Vivo Studies

Adult male Crl:CD (SD)IGS BR rats, approximately 8 weeks of age, were treated with NaI, PB, and PTU for 14 consecutive days. NaI, PB, and PTU were purchased from Sigma Chemical Company (St. Louis, MO). Rats (n = 20/group) were dosed by oral garage with vehicle (water or 0.25% methylcellulose), NaI (0.1, 1, 10, or 100 mg/kg/day), PB (100 mg/kg/day), or PTU (10 mg/kg/day) at a dose volume of 5 mL/kg. NaI was dissolved in water, whereas PB and PTU were dissolved in methylcellulose. On day 15, all rats were euthanized by carbon dioxide anesthesia and exsanguination. Blood samples were collected from the inferior vena cava of each animal at necropsy to measure serum levels of TSH, [T.sub.4], [T.sub.3], and reverse [T.sub.3] (r[T.sub.3]). Terminal body, thyroid gland, and liver weights were recorded for the first 10 animals of each dose group. The thyroid gland and surrounding tissue from the first 10 animals of each dose group were processed for histopathological evaluation. A liver sample from the first five animals of each dose group was processed to measure 5'-deiodinase I (5'-DI) and uridine diphosphate-glucuronyltransferase (UDPGT) activity. Thyroid glands from the last 10 animals (five from methylcellulose group) from each dose group were removed and placed in RNALater (Ambion, Austin, TX) overnight at 4[degrees]C. The next day, thyroids were removed from the RNALater and stored at -80[degrees]C until processed for total RNA.

The research described in this publication was conducted in a laboratory accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International, and the investigators complied with the regulations and standards of the Animal Welfare Act and adhered to the principles of the Guide for the Care and Use of Laboratory Animals (National Research Council 1996).

Pathological Evaluations

After euthanization the thyroid glands and surrounding tissue from the first 10 animals from each group were removed and placed into formalin fixative for at least 48 hr before trimming and weighing. After fixation, one individual performed a final dissection under a dissecting microscope. This was done in order to reduce the variability of the dissection procedure, thereby reducing the variability of the thyroid gland weights. Organ weights were calculated relative to body weight. The formalin-fixed thyroid glands were examined microscopically.

Hormonal Measurements

Blood was collected at the time of euthanization from all animals. Serum was prepared and stored between -65[degrees]C and -85[degrees]C until analyzed for serum hormone concentrations. Serum TSH (Amersham Biosciences Corp., Piscataway, NJ), [T.sub.3] and [T.sub.4] (Diagnostic Products Corp., Los Angeles, CA), and r[T.sub.3] (Polymedco Corp., Cortlandt Manor, NY) concentrations were measured using commercially available RIA kits.

Microsomal Preparations

At necropsy, a section of the liver from the first five animals from each group was removed, and hepatic microsomes were prepared for biochemical evaluation. A portion of the liver was homogenized (1 g tissue/8 mL buffer) in buffer containing 50 mM Tris-HCl, 0.25 M sucrose, and 5.4 mM EDTA, pH 7.4. The homogenates were centrifuged at 15,000 x g for 15 min at 4[degrees]C. The resulting supernatants were removed and centrifuged at 100,000 x g for 70 min at 4[degrees]C; these pellets contained the microsomal fractions. The microsomal pellets were resuspended in the homogenization buffer at a protein concentration of 10-20 mg/mL, aliquoted, and stored between -65[degrees]C and -85[degrees]C until analyzed for UDPGT and 5'-DI. The protein content of the microsomes was measured before and after analyses by the BioRad method (Bradford 1976). Final calculations were based on the postassay protein determination.

5'-Deiodenase I Measurements

Microsomal 5'-DI activity was determined using modifications of the methods of Pazos-Moura et al. (1991) and Leonard and Rosenberg (1980). Briefly, 50 [micro]L of reaction mixture [0.1 M potassium phosphate, 1 mM EDTA, 0.5 mM DTT, 14.5 [micro]L [125I]r[T.sub.3] (~ 4.9 [micro]Ci, 0.05 nmol)] was preincubated at 37[degrees]C for approximately 1 min. Fifty microliters of microsomes, diluted with liver homogenization buffer to achieve a final protein concentration of 0.5 mg/mL, was added to the reaction mixture. The tubes were vortexed and incubated for 10 min at 37[degrees]C. The reaction was stopped by the addition of 33 pL of ice-cold BSA-PTU solution (4% BSA, 5 mM PTU) and 133 [micro]L of 20% TCA, and the tubes were placed on ice until centrifugation. All tubes were centrifuged for 3 min at 12,000xg, 4[degrees]C. Two hundred microliters of the resulting supernatant (75% of the reaction volume) was applied to a Poly-Prep column equilibrated with 10% acetic acid, and eluted with 1.7 mL of 10% acetic acid. The resulting eluate was measured on a gamma counter to determine 5-DI activity (nmoles [[sup.125]I]r[T.sub.3] deiodinated per hour per milligram protein).

UDPGT Measurements

Microsomal UDPGT activity was determined spectrophotometrically using a modification of the method of Bock et al. (1983). Briefly, 15 [micro]L of p-nitrophenol (66.7 mM) was added to 460 [micro]L of microsomes, which had been resuspended with assay buffer [66 mM Tris-HCl, 10 mM magnesium chloride, 0.05% Brij 58 (polyoxyethylene ether 2 cetyl ether; CAS no. 9004-95-9), pH 7.5] to achieve a final protein concentration of 0.5-1.0 mg/mL. The tubes were preincubated at 37[degrees]C for 2 min before the addition of 25 [micro]L UDPGA (uridine diphosphate glucuronic acid; 200 mM) to start the reaction. The tubes were vortexed and incubated for 10 min at 37[degrees]C. A reaction blank tube for each sample was run concurrently by substituting the UDPGA with assay buffer. The reaction was stopped by the addition of 0.5 mL ice-cold methanol, and the tubes were placed on ice until centrifugation. All tubes were centrifuged for 10 min at 2,000x at 4[degrees]C. Three hundred microliters of the supernatant was combined with 2.7 mL 0.1 N sodium hydroxide, and the absorbance at 405 nm was measured. Rate of UDPGT activity is expressed as nmoles per minute per milligram protein.

Microarray Analysis

RNA preparation and analysis was done according to the Affymetrix-recommended protocol (Affymetrix 2002). Briefly, total RNA from four animals from each dose group was prepared individually using the TRIzol procedure (Invitrogen, Carlsbad, CA) and cleaned using the Qiagen RNeasy mini RNA cleanup protocol (Qiagen, Valencia, CA). The integrity of each RNA sample was determined using an Agilent 2100 Bioanalyzer (Agilent, Foster City, CA). After this, double-stranded cDNA from three of the four samples was prepared from 16 [micro]g of total RNA using Superscript II reverse transcriptase (Invitrogen) and a T7 primer (Genset, Boulder, CO) for first-strand synthesis, and DNA polymerase and ligase (Invitrogen) for second-strand synthesis. Subsequently, labeled cRNA was synthesized from the cDNA using the Enzo RNA transcript labeling kit (Affymetrix, Santa Clara, CA) according to the manufacturer's instructions. Approximately 20 [micro]g of biotin-labeled cRNA was then fragmented in a solution of 40 mM Tris-acetate, pH 8.1, 100 mM KOAc, and 30 mM MgOAc at 94[degrees]C for 35 min. Labeled cRNA was hybridized to the Affymetrix GeneChip Test2 Array (Affymetrix) to verify the quality of labeled cRNA. After this, cRNA was hybridized to the Affymetrix Rat Genome U34A GeneChip Probe Array (RG-U34A; Affymetrix). The cRNA in hybridization cocktail was incubated overnight at 45[degrees]C while rotating in a hybridization oven. After approximately 16 hr of hybridization, the cocktail was removed and the arrays were washed and stained in a Fluidics Station 400 (Affymetrix) according to the Affymetrix-recommended protocol (Affymetrix 2002). Briefly, several cycles of washes were done initially with a nonstringent buffer (1 M NaCl, 67 mM Na[H.sub.2]P[O.sub.4], 6.7 mM EDTA, 0.01% Tween 20) at 25[degrees]C and then with stringent buffer [100 mM MES, 0.1 M [Na.sup.+], 0.01% Tween 20] at 50[degrees]C. The arrays were then stained in streptavidin phycoerythrin (SAPE) solution (10 [micro]g/mL SAPE, 2 mg/mL acetylated BSA, 100 mM MES, 1 M Na+, 0.05% Tween 20) at 25[degrees]C, washed in nonstringent buffer, stained in antibody solution (2 mg/mL acetylated BSA, 100 mM MES, 1 M [[Na.sup.+]], 0.05% Tween 20, 0.1 mg/mL normal goat IgG, 3 [micro]g/mL anti-streptavidin biotinylated antibody) at 25[degrees]C, stained again in SAPE solution at 25[degrees]C, and then washed again in nonstringent buffer at 30[degrees]C. Arrays were then scanned on a GeneArray scanner (Agilent). Image analysis, quantification of raw gene expression values, mismatched probe background subtraction, and present/absent calls were performed using the Microarray Suite software (version 5.0; Affymetrix).

Data Analysis

Differential gene expression was determined by the regularized t-test, which uses a Bayesian procedure (Baldi and Long 2001). Briefly, the expression level of each gene is assumed to be from a normal distribution with [mu] and [[sigma].sup.2]. Using a conjugate prior, the mean of the posterior (MP) estimate of [mu] is the sample mean. The MP estimate of [[sigma].sup.2] is

[[sigma].sup.2] = [v.sub.0][[sigma].sup.2.sub.0] + (n - 1)[s.sup.2]/[v.sub.0] + n - 2,

where n is the sample size, [s.sup.2] is the sample variance, [v.sub.0] is the degrees of freedom of the prior (a value of 10 is used in the analysis), and [sigma][0.sup.2] is the mean of sample variances of genes in the neighborhood of the gene under consideration. The neighborhood is the 50 genes with sample means immediately above and below the sample mean of the gene under consideration; that is, the neighborhood consists of the 101 genes centered on the gene. After the MP estimates of [mu] and [[sigma].sup.2] are obtained, the t-test of unequal variances is used to calculate a p-value of differential expression.

Multiple linear regressions are used to determine dose-dependent expression after NaI treatments of 0.1, 1, 10, or 100 mg/kg/day. Some genes respond to NaI linearly, but for other genes, the induction or repression of expression may become saturated after some dose levels. Therefore, two types of multiple linear regressions were performed. The first type was the linear regression of the gene expression levels and the dose levels, and the other type was the linear regression of the gene expression levels and the logarithms of the dose levels.

A principal component analysis was also performed on the data. Three animals were measured within each treatment for each gene. The treatment means were then subjected to principal component analysis. The components were thus determined on a per-treatment basis rather than a per-gene basis, as in Raychaudhuri et al. (2000). For each of the treatments, the mean of the transcription signals was computed. Then, for each treatment, the ratio of the treatment mean to the corresponding control mean was computed. The logarithms of these six signal ratios were then analyzed. There was no need to standardize these log-ratios, because they were essentially standardized without further attention.

Results

Liver Weights and Hormone Metabolism

After the 2-week exposure period, liver weights were increased in a dose-dependent manner and were significantly higher in rats administered 10 and 100 mg/kg/day NaI (8-13% increase) and 100 mg/kg/day PB (44% increase) compared with control rats that received water alone (Figure 1). Liver weights were slightly reduced in animals that received 10 mg/kg/day PTU, and this was attributed to concomitant reductions in body weight in this treatment group (data not shown).

UDPGT activity was significantly higher (99% increase) in rats administered 100 mg/ kg/day PB compared with controls (Figure 1). In contrast, UDPGT activity was reduced (28% decrease) in rats that received 100 mg/ kg/day NaI for 2 weeks. 5'-DI activity was dramatically reduced in PTU-treated animals (93% decrease), whereas all other treatments had no significant change in activity compared with controls (Figure 1).

Thyroid Hormone Levels and Histopathology

Treatment-related effects on thyroid hormone levels were observed in the 100 mg/kg/day PB and 10 mg/kg/day PTU groups. Compared with controls, [T.sub.3], [T.sub.4], and r[T.sub.3] levels were reduced 23, 40, and 28%, respectively, in PB-treated rats and 80, 99, and 56%, respectively, in PTU-treated rats (Table 1). TSH levels were increased approximately 2- and 4-fold in PB- and PTU-treated rats, respectively. There were no treatment-related effects on thyroid hormone levels observed with NaI at any concentration tested.

Treatment-related changes in thyroid gland histopathology were observed in the PB and PTU treatment groups (Table 2). Thyroid follicular cell hypertrophy and pale-staining colloid were observed in both PB and PTU treatment groups, and diffuse hyperplasia was observed in the PTU group. Relative thyroid gland weights (percent of body weight) were also significantly increased (~ 3-fold) in the PTU treatment group compared with controls (Table 2). No treatment-related changes in thyroid gland histopathology were observed after NaI administration at any of the doses tested.

Thyroid Gland Gene Expression

Principal component analysis. Thyroid gene expression data were analyzed using principal component analysis, a regularized t-test and multiple linear regressions. Principal component analysis of gene expression data from all 24 samples demonstrated grouping according to treatment. Six principal components were identified (Table 3). Of these, the first four account for approximately 85% of the total variation in the data. Neither of the remaining two meets the 70/N rule used by Raychaudhuri et al. (2000). The general methodology of that reference was followed in the present analysis. To understand these principal components, it is helpful to express each as a linear combination of the means of the six treatments (Table 4). The first component is essentially the average of the NaI treatment log-signal ratios. Large values of this component tend to be associated with up-regulation in one or more NaI treatments. Large negative values (i.e., negative numbers large in absolute value) of this component tend to be associated with down-regulation in one of more NaI treatments. The second component is an indicator for an effect due to PB and PTU. A large value of Pcomp2 (principal component 2) indicates an up-regulation, whereas a large negative value indicates a down-regulation. Component 3 is primarily a contrast between the PB and PTU treatments. The fourth principal component is primarily an indicator of effect at low doses of NaI. Based on these principal component analysis findings, further gene ontology work was directed to the first two principal components, namely, genomic profiles associated with NaI exposure or PB and PTU exposure.

Multiple linear regressions. Dose-dependent expression, as determined by multiple linear regressions, was observed after NaI treatment. Transcript levels most influenced by dose (p [less than or equal to] 0.001), included the NIS [Slc5a5; GenBank accession no. U60282; (http:// www.ncbi.nlm.gov)] and antioxidant enzymes such as glutathione peroxidase 2 (Gpx2), thioredoxin reductase (Txnrd1), and glutathione S-transferase pi (GST-pi; Gstp2) (Table 5). NIS mRNA was down-regulated in a dose-dependent manner to 80 (not statistically significant), 40, 30, and 20% of control values after 0.1, 1, 10, and 100 mg/kg/day NaI, respectively (Figure 2A). However, unlike NaI, PTU increased NIS expression by greater than 300% of control, and PB only slightly reduced (70% of control) NIS transcript levels. The most statistically significant of the antioxidant enzymes, GST-pi, was up-regulated to 154, 196, 263, and 250% of control values after the same NaI dosing regimen (Figure 2B). Similar to NaI, PB and PTU increased GST-pi expression levels to 198 and 265% of control, respectively.

[FIGURE 2 OMITTED]

Regularized t-test (Bayesian procedure). In a separate analysis using the regularized t-test, 872, 948, and 1552 gene transcripts (of 8,740 transcripts present in all samples) were significantly (p < 0.01) changed by 100 mg/kg/day NaI, 100 mg/kg/day PB, and 10 mg/kg/day PTU administration compared with controls, respectively. To further characterize these genomic changes according to biological function and identify molecular pathways involved in the mode of action of each chemical, these gene lists were uploaded into GenMAPP (Gene Map Annotator and Pathway Profiler, version 1.0; Dahlquist et al. 2002). Two molecular pathways found to be highly influenced by NaI were rhodopsin-like G-protein receptors and oxidative-stress-related genes (Table 5). These pathways were also influenced by PB and PTU treatment, although the spectrum of gene transcripts was unique for each chemical. Although all chemicals affected the expression of one or more adrenergic receptors, dopamine and chemokine receptor transcripts were only affected by PB and PTU treatment, respectively. PB and PTU also caused a down-regulation of TSH receptor mRNA (Table 5) correlating with the increased circulating TSH observed with these chemicals from the serum hormone analysis. Interestingly, NaI induced specific changes in multiple olfactory receptor and oxidative stress transcripts, including Txnrd1, Gpx2, superoxide dismutase 2 (Sod2), and nitric oxide synthase 2 (Nos2), that were not affected by PB or PTU treatment (Table 5). NaI also altered the levels of multiple transcripts involved in apoptosis that were not affected by PB or PTU treatment including receptor-interacting serine-threonine kinase 3 [Ripk3, GenBank accession no. AF036537 (http://www.ncbi.nlm.nih.gov)], BH3 interacting domain 3 [Bid3; GenBank accession no. AI102299 (http://www.ncbi.nlm.nih.gov)], and scavenger receptor class B [Scarb1; GenBank accession no. D89655 (http://www. ncbi.nlm.nih.gov); p < 0.001]

To further identify discriminating molecular pathways that might be predictive of thyroid pathology and cancer risk, additional emphasis was placed on molecular pathways affected by both PB and PTU but not NaI. Interestingly, large differences were observed in transcripts from ribosomal protein and Wnt signaling gene families. Although not observed after Na/exposure, multiple 40S ribosomal protein transcripts were significantly reduced by PTU and PB treatment, including S4 (Rps4), S6 (Rps6), and S8 (Rps8) proteins (Table 6). NaI-dependent changes in ribosomal transcripts were observed in the large 60S subunit that included L22 (Rpl22) and L18 (Rpl18a) ribosomal proteins. Wnt target gene transcripts cyclin D1 (Ccnd1), c-jun (]un), insulin-like growth factor binding protein (Igfbp2), VEGF receptor (Kdr), and protein kinase C (PKC) [zeta] (Prkcz) were up-regulated 50-300% in thyroids from PB- and PTU-treated animals, whereas no treatment-related changes in these transcripts were observed after NaI exposure (Table 6; Figure 3). PTU also altered the expression of other Wnt target genes, including multiple cyclin D3 (Ccnd3) transcripts and urokinase plasminogen activator receptor (Plau) mRNA (Table 6, Figure 3). Decreased expression of the adenomatous polyposis coli (Apc) gene and/or its homologs was also observed after exposure to PB and PTU. Finally, a modest increase (40%) in frizzled protein (Fzd1) mRNA was observed on a single gene target from the NaI treatment group. Multiple protein kinase transcripts were affected by PB and/or PTU exposure, including the up-regulation of Prkcz (PB and PTU) and PKC[alpha] (Prkca), and down-regulation of protein kinase A [Prkaa; GenBank accession no. X57986 (http://www.ncbi.nlm.nih.gov); PTU only]. In contrast, NaI did not significantly alter the transcript levels of any protein kinase (Table 6; Figure 3).

[FIGURE 3 OMITTED]

Discussion

Many organic iodides alter rat thyroid homeostasis that may potentially lead to thyroid tumors after chronic administration (Capen 1997; Hurley et al. 1998). Although chemically induced changes in thyroid hormone metabolism and thyroid hormone release have been associated with increased thyroid tumor incidence in rodents, no such correlation with cancer risk has been associated with excess iodide (Capen 1997; Markou et al. 2001). To better characterize thyroid toxicity associated with increased cancer risk in the rat, genomic, clinical, and pathological end points were examined in response to excess NaI (non-carcinogen) and the rodent thyroid carcinogens PB and PTU in a modified 2-week endocrine battery (O'Connor et al. 2002).

Similar to previous reports, PB and PTU caused hormonal alterations (reduced serum [T.sub.3], r[T.sub.3], and [T.sub.4] levels and increased TSH) and induced thyroid follicular cell hypertrophy in male rats after a 2-week exposure period (De Sandro et al. 1991). PB also increased relative liver weights (percent of body weight) and hepatic UDPGT activity, suggesting the involvement of altered thyroid hormone metabolism in PB-induced thyroid toxicity (Barter and Klassen 1992). In contrast, PTU reduced hepatic 5'-DI activity, increased relative thyroid weights (percent body weight), and induced thyroid follicular cell hyperplasia in male rats, suggesting an alternative mechanism of toxicity, including peripheral conversion of [T.sub.4] to [T.sub.3] (Oppenheimer et al. 1972). These effects elicited by PB and PTU in this short-term study, specifically, increases in TSH levels resulting in microscopic alterations of the thyroid gland, are suggestive of a potential thyroid tumor response after longer-term exposures in male rats (Capen 1997).

No biologically significant effects were observed after NaI exposure using the same treatment regimen. NaI caused no changes in thyroid hormone levels or thyroid histopathology. UDPGT activity was statistically significantly reduced in rats dosed with 100 mg/kg/day NaI, although liver weights were significantly increased in male rats receiving 10 and 100 mg/kg/day NaI. The significance of these effects on hepatic UDPGT activity is unclear but suggests an alternative effect on liver metabolism despite the concomitant increase in liver weights. These dose-dependent effects demonstrate for the first time that excess iodide can elicit a biological/toxicological response on the liver. The importance of these observed liver effects are also supported by the fact that iodide doses used in this study (1-10 mg/kg/day) are obtainable in high-dose toxicology studies with iodinated compounds.

We found multiple gene transcripts that were significantly altered by linear regression, regularized t-test, and principle component analysis models in response to NaI treatment. The transcripts most sensitive to iodide exposure included the thyroid NIS and GST-pi. NIS mRNA was significantly reduced to 40% of control levels at NaI doses as low as 1 mg/kg/day. A similar reduction in NIS mRNA has been reported previously after 6 days of exposure to 0.05% NaI in the drinking water of rats (Eng et al. 1999). In that study a concomitant reduction in protein level was also demonstrated suggestive of reduced iodide transport into the thyroid. In our study, GST-pi mRNA was significantly increased (150% of control) in the thyroid of rats exposed to the lowest dose of NaI tested (0.1 mg/kg/day). The biologic significance of increased GST-pi (Gstp2) transcripts in the rat thyroid is uncertain but may be predictive of increased oxidative stress. Other antioxidant gene transcripts were induced in the rat thyroid after NaI exposure, including Gpx1 and Gpx2 (1.4- and 2.4-fold, respectively), Sod2 (1.6 fold), Txnrd1 (1.5-fold), heme oxygenase (Hmox1, 1.9-fold), and NAD(P)H dehydrogenase quinone (Nqo1, 2.2-fold; Table 5). Iodide increases oxidative stress in cultured thyroid cells as evidenced by increased intracellular reactive oxygen species and lipid peroxidation (Vitale et al. 2000). It has been suggested that [I.sub.2], the molecular form of ionic iodide, is highly reactive with protein, lipids, and nucleic acids and that generation of iodocompounds may disrupt cellular membrane functions, increase reactive oxygen species, and cause programmed cell death in thyroid cells. Dose-dependent increases in the antioxidant enzyme transcripts Gpx2 and Gstp2 observed in the rat thyroid are consistent with a compensatory response to the generation of lipid peroxides as reported by Vitale et al (2000) using iodide exposures in vitro. The observed alterations in multiple transcripts involved in apoptosis in our studies are also consistent with this proposed mechanism of iodide-induced thyroid toxicity.

NaI exposure also influenced the mRNA expression of a wide range of rhodopsin-like G-protein-coupled receptors including adrenergic receptors. NaI increased [beta]-adrenergic receptor (Adrb2) gene expression in a dose-dependent manner, whereas PB and PTU increased 0q-adrenergic receptor (Adra1d) gene expression. In previous in vitro studies, thyrotropin (TSH) increased [[alpha].sub.1]-adrenergic receptor mRNA in rat thyroid FRTL-5 cells as a compensatory mechanism to down-regulate TSH-induced cAMP levels (Corda and Kohn 1985). cAMP is considered the primary second messenger in thyroid follicular cell growth and maintenance (Medina and Santisteban 2000; Richards 2001). Together with the observed reduction in TSH receptor mRNA observed in the thyroids of rats exposed to PB and PTU, these gene expression changes are suggestive of an adaptive response to high levels of circulating TSH seen in rats treated with PB and PTU but not NaI. Further investigation is needed to understand the biological significance, if any, of [beta]-adrenergic receptor mRNA induction by NaI.

To further identify gene expression changes that may be predictive of cancer risk, additional emphasis was placed on signaling pathways influenced by PB and PTU (carcinogens) but not NaI (noncarcinogen). Interestingly, significant changes were observed in gene expression patterns associated with Wnt signaling in PB and PTU exposed animals. Up-regulation of Ccnd1, Ccnd3, and Jun mRNA (all transcriptional targets of Wnt signaling) are suggestive of increased risk to human cancer (Behrens 2000; Ishigaki et al. 2002). Cyclin D1 protein is overexpressed in human thyroid cancers that have causal links to environmental radiation exposures at nuclear test sites (Meirmanov et al. 2003). Cyclin D1 and cyclin D3 both facilitate entry into the cell cycle, and increased transcription of these genes is associated with increased cell proliferation and hyperplasia (Baldassarre et al. 2003; Ishigaki et al. 2002). Thyroid hyperplasia was only observed in PTU animals and not PB animals (hypertrophy was observed in both groups), suggesting that increased expression of these genes precedes visible histopathological changes. Finally, the proto-oncogene Jun, which is also associated with multiple types of human cancer, mediates its oncogenic activity by stimulating AP-1-mediated transcription and cell proliferation (Shaulian and Karin 2001). Up-regulation of Jun has been associated with thyroid cancer, but its importance in mediating Wnt signaling in the thyroid has yet to be characterized (Battista et al. 1998).

Increased [beta]-catenin protein is a common marker for Wnt signaling in multiple types of cancer, including thyroid cancer (Behrens 2000). [beta]-Catenin complexes with the adenomatous polyposis coli (Apc) gene and axin to regulate its phosphorylation by glycogen synthase kinase (Gsk3b) and subsequent proteosomal degradation (Henderson and Fagotto 2002). Wnt activation inhibits the phosphorylation of [beta]-catenin, resulting in its nuclear accumulation, binding to the lymphoid enhancer factor-1/T-cell-specific transcription factor (LEF-1/TCF), and transcription of multiple target genes as previously discussed (Kikuchi 2000). Interestingly, significantly lower gene expression levels of Apc and/or two other tumor suppressor proteins with homologous sequence mRNAs were observed in the thyroid glands of animals treated with PB and PTU but not NaI. In addition, mRNA expression of Prkcz, an inhibitor of Gsk3b kinase activity, was up-regulated in response to PB and PTU animals but not NaI (Oriente et al. 2001). Inhibition of Gsk3b results in decreased phosphorylation of [beta]-catenin and causes its nuclear accumulation. Lastly, a DNA damage protein (Gadd45a) and a MAP kinase (Mapk14), two other proteins recently associated with Wnt activation, were also differentially expressed in PB- and PTU-treated animals but not in NaI-treated animals (Hildesheim et al. 2004).

In further support of our findings, recent investigations have also demonstrated silencing of Wnt signaling in mammalian cells after exposures to thyroid hormone ([T.sub.3]; Miller et al. 2001; Natsume et al. 2003). In these studies [T.sub.3] inhibited [beta]-catenin accumulation and transcriptional activity in rat pituitary and human kidney cells, respectively. Although [T.sub.3] promotes cellular growth in many cellular systems, it is suggested that [T.sub.3] involvement in normal organ development and cellular differentiation also implies antitumor activity of this critical hormone. In our studies, reductions in thyroid hormone were only observed in PB- and PTU-treated animals with the most significant changes after PTU exposure. This correlates well with the magnitude and number of Wnt signaling target genes changed in the microarray analyses of each treatment group.

Finally, significant changes in ribosomal protein mRNA were also observed in PB- and PTU-exposed animals. Alterations in ribosomal protein expression have been associated with increased cell proliferation and hyperplasia in multiple tissue types (Chou and Blenis 1995; Hamadeh et al. 2002). The ribosomal protein Rps6, regulated by p70 ribosomal $6 kinase (pp[70.sup.s6k]), is important in transcription and translation events precluding entry into the cell cycle (Cass and Meinkoth 1998). The mRNA of this protein was down-regulated in PB- and PTU-treated animals, correlating with other cAMP signaling responses (protein kinase mRNA regulation) observed in this study.

In summary, we present new findings with regard to thyroid gene expression in the rat after subchronic exposure to NaI, PB, and PTU. Although no significant changes in biochemical and pathological measurements of thyroid function were observed in the rat after NaI exposure, significant changes in thyroid gene expression were observed even at the lowest concentration of NaI tested (0.1 mg/kg/day). Many of these genes, namely, multiple antioxidant enzymes have not been characterized previously in the rat thyroid and may prove useful as biomarkers of iodide exposure. We also demonstrate gene expression changes associated with thyroid histopathology and hormone status after PB and PTU exposures. Expression patterns of Wnt signaling genes correlated with circulating thyroid hormone levels, thyroid histopathology, and the carcinogenic potential of PB and PTU in the rat. The potential interactions between these mechanisms of thyroid toxicity are summarized in Figure 4. We suggest that organic iodides may elicit changes in circulating- hormone levels as well as cause increases in oxidative stress in the rat thyroid. Although excess iodide may not cause follicular cell transformation via activation of Wnt signaling, it may enhance cytotoxicity in the rat thyroid exacerbated by thyroid pathology caused by fluctuations in thyroid hormone levels. These findings, in addition to further elucidating signaling pathways that correlate with rat thyroid pathology, may provide useful biomarkers for the prediction of thyroid tumorigenesis after chronic exposure to xenobiotics in the rat.

[FIGURE 4 OMITTED]

REFERENCES

Affymetrix. 2002. GeneChip Expression Analysis Technical Manual. Santa Clara, CA:Affymetrix.

Backer H, Hollowell J. 2000. Use of iodine for water disinfection: iodine toxicity and maximum recommended dose. Environ Health Perspect 108:679-684.

Baldassarre G, Palombini L, Fusco A, Viglietto G. 2003. Critical role of cyclin D3 in TSH dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland. 0ncogene 22:7575-7586.

Baldi P, Long, AD 2001. A Bayesian framework for the analysis of microarray expression data: regularized t test and statistical inferences of gone changes. Bioinformatics 17:509-519.

Barter R, Klassen C. 1992. UDP-glucuonosyltransferase inducers reduce thyroid hormone levels in rats by an extrathyroidal mechanism. Toxicol Appl Pharmacol 111:36-42.

Battista S, de Nigris F, Fedele M, Chiappetta O, Scala S, Vallone D, et al. 1998. Increase in AP-1 activity is a general event in thyroid cell transformation in vitro and in vivo. Oncogene 17:377-385.

Behrens J. 2000. Control of [beta]-catenin signaling in tumor development. Ann NY Acad Sci 910:21-33.

Bock KW, Burchell B, Dutton GJ, Hanninen O, Mulder GJ, Owens IS, et al 1983. UDP glucuronosyltransferase activities: guidelines for consistent interim terminology and assay conditions. Biochem Pharmacol 32:953-955.

Bradford MM 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:249-254.

Capen CC. 1997. Mechanistic data and risk assessment of selected toxic end points of the thyroid gland. Toxicol Pathol 25:39-48.

Cass LA, Meinkoth JL. 1998. Differential effects of cyclic adenosine 3',5'-monophosphate on p70 ribosomal S6 kinase. Endocrinology 139:1991-1998.

Chou MM, Blenis J. 1995. The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signaling. Curr Opin Cell Biol 7:806-814.

Corda D, Kohn LD. 1985. Thyrotropin upregulates [[alpha].sub.1]-adrenergic receptors in rat FRTL 5 thyroid cells. Proc Natl Acad Sci USA 82:8677-8680.

Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. 2002. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet 31:19-20.

De Sandro V, Chewier M, Boddaert A, Melcion C, Cordier A, Richert L. 1991. Comparison of the effects of propylthiouracil, amiodarone, diphenylhydantoin, phenobarbitol, and 3-methylcholanthrene on hepatic and renal [T.sub.4] metabolism and thyroid gland function in rats. Toxicol Appl Pharmacol 111:203-278.

Eng PH, Cardona OR, Fang SL, Previti M, Alex S, Carrasco N, et al. 1999. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 140:3404-3410.

Hamadeh HK, Knight BL, Haugen AC, Sieber S, Amin RP, Bushel PR, et al. 2002. Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol Pathol 30:470-482.

Hard GC. 1998. Recent developments in the investigation of thyroid regulation and thyroid carcinogenesis. Environ Health Perspect 106:427-436.

Henderson BR, Fagotto F. 2002. The ins and outs of APC and [beta]-catenin nuclear transport. EMBO Rep3:834-839.

Hildesheim J, Belova GI, Tyner SO, Zhou X, Vardanian L, Fornace AJ. 2004.6add45a regulates matrix metalloproteinases by suppressing DeltaNp63[alpha] and [beta]-catenin via p38 MAP kinase and APC complex activation. Oncogene 23:1829-1837.

Hill RN, Crisp TM, Hurley PM, Rosenthal SL, Singh DV. 1998. Risk assessment of thyroid follicular cell tumors. Environ Health Perspect 106:447-457.

Hood A, Liu YP, Gattone III VH, Klaassen CD. 1999. Sensitivity of thyroid gland growth to thyroid stimulating hormone (TSH) in rats treated with antithyroid drugs. Toxicol Sci 49:263-271.

Hurley PM, Hill RN, Whiting RJ. 1998. Mode of carcinogenic action of pesticides inducingthyroid follicular cell tumors in rodents. Environ Health Perspect 106:437-445.

Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, et al. 2002. Aberrant localization of [beta]-catenin correlates with overexpression of its target gene in human papillary-thyroid cancer. J Clin Endocrinol Metab 87: 3433-3440.

Kanno J, Nemoto T, Kasuga T, Hayashi Y. 1994. Effects of a six-week exposure to excess iodide on thyroid glands of growing and non-growing male Fischer 344 rats. Toxicol Pathol 22:23-28.

Kanno J, 0nodera H, Furuta K, Maekawa A, Kasuga T, Hayashi Y. 1992. Tumor-promoting effects of both iodine deficiency and iodine excess in the rat thyroid. Toxicol Pathol 20:226-235.

Kikuchi A. 2000. Regulation of [beta]-catenin signaling in the Wnt pathway. Biochem Biophys Res Comm 268:243-248.

Leonard JL, Rosenberg IN. 1980. Iodothyronine 5'-deiodinase from rat kidney: substrate specificity and the 5'deiodination of reverse triodothyronine. Endocrinology 107:1376-1382.

Markou K, Georgopoulos N, Kyriazopoulou V, Vagenakis A6. 2001. Iodine-induced hypothyroidism. Thyroid 11:501-510.

McClain RM. 1992. Thyroid gland neoplasia: non-genotoxic mechanisms. Toxicol Lett 64:397-408.

McClain RM, Posch RC, Bosakowski T, Armstrong JM. 1988. Studies on the mode of action for thyroid gland tumor promotion by phenobarbital. Toxicol Appl Pharmacol 94:254-265.

Medina DL, Santisteban P. 2000. Thyrotropin-dependent proliferation of in vitro rat thyroid cell systems. Euro J Endocrinol 143:161-178.

Meirmanov S, Nakashima M, Kondo H, Matsufuji R, Takamura N, Ishigaki K, et al. 2003. Correlation of cytoplasmic [beta]-catenin and cyclin D1 overexpression during thyroid carcinogenesis around Semipalatinsk nuclear test site. Thyroid 13:537-545.

Miller LD, Park KS, Guo QM, Alkharouf NW, Malek RL, Lee NH, et el. 2001. Silencing of Wnt signaling and activation of multiple metabolic pathways in response to thyroid hormone-stimulated cell proliferation. Mol Cell Biol 21:6626-6639.

National Research Council. 1996. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press.

Natsume H, Sasaki S, Kitagawa M, Kashiwabara Y, Matsushita A, Nakano K, et al. 2003. [beta]-Catenin/Tcf-1 mediated transactivation of cyclin D1 promoter is negatively regulated by thyroid hormone. Biochem Biophys Res Comm 309:408-413.

O'Connor JC, Cook JC, Marty MS, Davis LG, Kaplan AM, Carney EW. 2002. Evaluation of Tier 1 screening approaches for detecting endocrine-active compounds (EACs). Crit Rev Toxicol 32:521-549.

Oppenheimer JH, Schwartz HL, Surks MI. 1972. Propylthiouracil inhibits the conversion of L-thyroxine to L-triiodothyronine: an explanation of the antithyroxine effect of propylthiouracil and evidence supporting the concept that triiodothyronine is the active thyroid hormone. J Clin Invest 51:2493-2497.

Oriente F, Formisano P, Miele C, Fiery F, Maitan MA, Vigliotta G, et el. 2001. Insulin receptor substrate-2 phosphorylation is necessary for protein kinase C [zeta] activation by insulin in L6hlR cells. J Biol Chem 276:37109-37119.

Pazos-Moura CC, Moura EG, Dorris ML, Rehnmark S, Melendez L, Silva JE, et at 1991. Effect of iodine deficiency and cold exposure on thyroxine 5'-deiodenase activity in various rat tissues. Am J Physiol 260:E175-E182.

Raychaudhuri S, Stuart JM, Altman RB. 2000. Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Syrup Biocomput 5:855-866.

Richards JS. 2001. New signaling pathways for hormones and cyclic adenosine 3',5' monophosphate action in endocrine cells. Mol Endocrinol 15:209-218

Shaulian E, Karin M 2001. AP-1 in cell proliferation and survival. Oncogene 20:2399-2400.

Vitale M, Matola TD, D'Ascoli F, Salzano S, Bogazzi F, Fenzi G, et el. 2000. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 141:598-605.

Wolff J, Chaikoff IL. 1948. Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem 174:555-564.

Christine M. Glatt, (1) Ming Ouyang, (2) William Welsh, (2) John W. Green, (1) John O'Connor, (1) Steven R. Frame, (1) Nancy E. Everds, (1) Greg Poindexter, (1) Suzanne Snajdr, (1) and Don A. Delker (1)

(1) DuPont Haskell Laboratory, Newark, Delaware, USA; (2) Department of Pharmacology, Robert Wood Johnson Medical School and Informatics Institute of the University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey, USA

We acknowledge J. Stadler and B. Shertz for their help in study design and technical support, respectively. The authors declare they have no competing financial interests.

Address correspondence to D.A. Delker, Environmental Carcinogenesis Division, U.S. Environmental Protection Agency, 109 TW Alexander Dr. (B143-06), Durham, NC 27711 USA. Telephone: [phone]. Fax: [phone]. E-mail: [e-mail]

Received 22 October 2004; accepted 12 May 2005.

Table 1. Thyroid hormone parameters.

Treatment (mg/kg/day)   [T.sub.3] (ng/mL)      [T.sub.4] (ng/mL)

Water                   73.6 [+ or -] 12.5     4.23 [+ or -] 0.83
Nal (0.1)               75.6 [+ or -] 12.4     4.37 [+ or -] 0.92
Nal (1)                 69.0 [+ or -] 10.5     4.40 [+ or -] 1.01
Nal (10)                68.9 [+ or -] 10.4     4.38 [+ or -] 1.29
Nal (100)               73.3 [+ or -] 14.4     4.58 [+ or -] 1.14
PB (100)                56.5 [+ or -] 10.4 *   2.52 [+ or -] 0.84 *
PTU (10)                14.5 [+ or -] 7.3 *    0.04 [+ or -] 0.10 *

Treatment (mg/kg/day)      TSH (ng/dL)          r[T.sub.3] (ng/mL)

Water                   12.2 [+ or -] 6.1      0.111 [+ or -] 0.015
Nal (0.1)               10.7 [+ or -] 3.6      0.118 [+ or -] 0.018
Nal (1)                 11.5 [+ or -] 4.2      0.114 [+ or -] 0.022
Nal (10)                15.1 [+ or -] 7.8      0.106 [+ or -] 0.023
Nal (100)               13.1 [+ or -] 5.0      0.106 [+ or -] 0.020
PB (100)                22.4 [+ or -] 10.2 *   0.080 [+ or -] 0.024 *
PTU (10)                51.9 [+ or -] 12.4 *   0.049 [+ or -] 0.018 *

Values represent mean [+ or -] SD of 16 or more measurements from
individual animals in each group.

* Statistical significance from control as determined by
Jonckheere-Terpstra trend test, p < 0.05.

Table 2. Thyroid gland pathology.

Treatment (mg/kg/day)           Thyroid (g)          Colloid

Water                       0.006 [+ or -] 0.001        -
Nal(100)                    0.007 [+ or -] 0.002        -
PB(100)                     0.007 [+ or -] 0.001        +
PTU(10)                     0.018 [+ or -] 0.003 *      ++

Treatment (mg/kg/day)     Hypertrophy    Hyperplasia

Water                          -              --
Nal(100)                       -              --
PB(100)                        +              --
PTU(10)                        ++             ++

Abbreviations: -, no lesions observed; +, lesions observed; ++,
severe lesions observed. Values represent mean [+ or -] SD of
9-11 measurements from individual
animals in each group.

* Statistical significance from control as determined by least
significant difference and Dunnett's test, p < 0.05.

Table 3. Principal component analysis.

Principal component     Eigenvalue    Proportion    Cumulative

1                       2.53220382      0.4220        0.4220
2                       1.36004986      0.2267        0.6487
3                       0.69452426      0.1158        0.7645
4                       0.51077061      0.0851        0.8496
5                       0.49305017      0.0822        0.9318
6                       0.40940129      0.0682        1.0000

Table 4. Principal component values based on treatment group.

Variable       Pcomp1      Pcomp2      Pcomp3      Pcomp4

Lnsigrat3     0.491944   -0.079240    0.067459    0.816707
Lnsigrat5     0.502641   -0.050801    0.241487   -0.396262
Lnsigrat7     0.494279    0.023657    0.208137   -0.391877
Lnsigrat9     0.498959   -0.063955   -0.394606   -0.007669
Lnsigrat11    0.109047    0.688894   -0.627580   -0.063206
Lnsigrat13    0.013435    0.715482    0.586721    0.135445

Variable       Pcomp5      Pcomp6

Lnsigrat3     -0.153903  -0.237625
Lnsigrat5      0.480074  -0.546773
Lnsigrat7     -0.721315   0.194792
Lnsigrat9      0.406380   0.652712
Lnsigratl1    -0.133869  -0.312667
Lnsigrat13     0.206111   0.287812

Abbreviations: Lnsigrat#, natural logarithm of the transcription
signal ratio for treatment number; Pcomp#, principal component number.

Table 5. Treatment-related effects on rhodopsin-like G-protein-coupled
receptor and oxidative stress-related gene expression.

                                                            GenBank
Gene group/name (a)                      Gene symbol (a)   accession
                                                            no. (a)

Rhodopsin-like GPCRs
  Alpha-1D adrenergic receptor               Adra1d       M60654
  Alpha-1B adrenergic receptor               Adra1b       M60655
  Alpha-1C adrenergic receptor               Adra1c       U13368
  Alpha-2A adrenergic receptor               Adra2a       U79031
  Beta-2 adrenergic receptor                 Adrb2        J03024
  Beta-3 adrenergic receptor                 Adrb3        S56481
  Serotonin receptor 6                       Htr6         S62043
  Serotonin receptor 4                       Htr4         U20907
  Serotonin receptor 1F                      Htr1f        L05596
  Serotonin receptor 7                       Htr7         L22558
  Dopaminergic receptor D-3                  Drd3         A17753
  Opioid receptor mu-1                       Oprm1        D16349
  Cholinergic receptor muscarinic 3          Chrm3        M16407
  Cholinergic receptor muscarinic 5          Chrm5        M22926
  Neuropeptide Y5 receptor                   Npy5r        U66274
  Panceatic polypeptide receptor             Ppyr1        U42388
  Interleukin 8 receptor beta                I18rb        U70988
  Chemokine receptor 4                       Cxcr4        U90610
  Chemokine receptor 1                       Cx3cr1       U04808
  A3 adenosine receptor                       -- (b)      X93219
  Angiotensin II receptor                     --          M90065
  Angiotensin II receptor (AT1B)              --          X64052
  Thyroid-stimulating hormone receptor       Tshr         M34842
  Chemokine orphan receptor 1                Cmkor1       AJ010828
  Endothelin receptor type B                 Ednrb        X57764
  Prostaglandin E receptor 4                 Ptger4       D28860
  Platelet-activating factor receptor        Ptafr        U04740
  Bradykininreceptor B1                      Bdkrb1       AJ132230
  GABAB receptor 1                           Gabbr1       AB016161
  Olfactory receptor pseudogene              Olr1469      AF091570
  Olfactory receptor 1696                    Olr1696      AF034896
  Olfactory receptor 1699                    Olr1699      AF034899
  Olfactory receptor 226                     Olr226       M64386
  Olfactory receptor 1361                    Olr1361      M64377
  Olfactory receptor 1370                    Olr1370      AF091577
  Olfactory receptor 1493                    Olr1493      AF091572
  Olfactory receptor 1346                    Olr1346      AF091578
  Olfactory receptor 1687                    Olr1687      AF091563
Oxidative stress-related genes
  NAD(P)H dehydrogenase quinone              Nqo1         J02679
  Heme oxygenase 1                           Hmox1        J02722
  Glutamate-cysteine ligase                  Gclc         J05181
  Thioredoxin reductase 1                    Txnrd1       U63923
  Glutathione peroxidase 1                   Gpx1         X07365
  Glutathione peroxidase 2                   Gpx2         AA800587
  Glutathione reductase                      Gpr          U73174
  GST-pi                                     Gstp2        X02904
  Superoxide dismutase 3                     Sod3         X68041
  Superoxide dismutase 2                     Sod2         Y00497
  Superoxide dismutase 1                     Sod1         M25157
  Metallothionein-1a                         Mt1a         M11794
  Peroxiredoxin 1                            Prdx1        A1010083
  Nitric oxide synthase 2                    Nos2         U16359
  Cytochrome b-245 alpha                     Cyba         U18729
  Monoamine oxidase A                         --          S45812

Gene group/name (a)                         Nal       PB         PTU

Rhodopsin-like GPCRs
  Alpha-1D adrenergic receptor             -- (c)    1.6        3.0
  Alpha-1B adrenergic receptor             2.0       2.1        3.4
  Alpha-1C adrenergic receptor            -2.1        -- (c)     -- (C)
  Alpha-2A adrenergic receptor             1.9        --         --
  Beta-2 adrenergic receptor               2.9        --         --
  Beta-3 adrenergic receptor              -2.2        --       -2.1
  Serotonin receptor 6                    -1.6        --         --
  Serotonin receptor 4                      --        --        4.1
  Serotonin receptor 1F                     --       7.7         --
  Serotonin receptor 7                      --        --        2.5
  Dopaminergic receptor D-3                 --       3.4         --
  Opioid receptor mu-1                      --      -2.7         --
  Cholinergic receptor muscarinic 3         --        --       -1.7
  Cholinergic receptor muscarinic 5       -1.9        --         --
  Neuropeptide Y5 receptor                 2.1        --         --
  Panceatic polypeptide receptor          -2.1        --         --
  Interleukin 8 receptor beta               --        --       -2.0
  Chemokine receptor 4                      --        --        1.9
  Chemokine receptor 1                      --        --        2.1
  A3 adenosine receptor                   -2.8        --         --
  Angiotensin II receptor                   --        --       -1.8
  Angiotensin II receptor (AT1B)            --      -3.7         --
  Thyroid-stimulating hormone receptor      --      -1.6       -1.7
  Chemokine orphan receptor 1              1.5        --         --
  Endothelin receptor type B                --        --        1.6
  Prostaglandin E receptor 4                --        --        3.0
  Platelet-activating factor receptor       --        --        2.6
  Bradykininreceptor B1                   -1.4        --         --
  GABAB receptor 1                        -1.6        --         --
  Olfactory receptor pseudogene           -1.3        --         --
  Olfactory receptor 1696                 -1.7        --         --
  Olfactory receptor 1699                 -2.9        --         --
  Olfactory receptor 226                    --        --       -1.9
  Olfactory receptor 1361                 -2.0        --         --
  Olfactory receptor 1370                 -2.2        --         --
  Olfactory receptor 1493                 -2.4        --         --
  Olfactory receptor 1346                 -4.2        --         --
  Olfactory receptor 1687                 -5.3      -3.6         --
Oxidative stress-related genes
  NAD(P)H dehydrogenase quinone            2.2       1.5        2.0
  Heme oxygenase 1                         1.9       2.0         --
  Glutamate-cysteine ligase                1.5       1.5         --
  Thioredoxin reductase 1                  1.5        --         --
  Glutathione peroxidase 1                 1.4        --        1.4
  Glutathione peroxidase 2                 2.4        --         --
  Glutathione reductase                     --       1.6        1.6
  GST-pi                                   2.5       2.0        2.6
  Superoxide dismutase 3                  -1.4        --        1.7
  Superoxide dismutase 2                   1.6        --         --
  Superoxide dismutase 1                  -2.0        --         --
  Metallothionein-1a                      -1.7      -1.9       -2.1
  Peroxiredoxin 1                          1.2        --         --
  Nitric oxide synthase 2                  2.2        --         --
  Cytochrome b-245 alpha                   1.7        --        1.6
  Monoamine oxidase A                       --        --       -1.4

Values represent statistically significant (p< 0.01 by regularized
t-test) mean fold change from control (n=3) for 100 mg/kg/day Nal and
PB and 10 mg/kg/day PTU.

(a) From GenBank (http://www.ncbi.nlm.nih.gov). (b)--, Gene symbol
unknown. (c)--, Not statistically significant.

Table 6. Treatment-related effects on Wnt signaling and ribosomal
protein gene expression.

Gene group/names (a)                    Gene symbol (a)      GenBank
                                                            accession
                                                             no. (a)

Wnt signaling genes
  APC fragment 2 of 6                       -- (b)         L19304 (c)
  APC fragment 4 of 6                       --             L19306
  APC protein                               Apc            D38629
  c-jun oncogene                            Jun            X17163
  Cyclin D1                                 Ccnd1          D14014
  Cyclin 01 partial                         Ccnd1          X75207 (C)
  Cyclin 03                                 Ccnd3          D16309 (c)
  Cyclin 03 partial                         Ccnd3          U49935 (c)
  Frizzled homolog 1                        Pzd1           L02529
  DNA damage inducible transcript           Gadd45a        L32591
  Insulin-like factor binding protein       lgfbp2         M91595
  Low-density lipoprotein receptor          Ldlr           X13722
  p38 MAP kinase                            Mapk14         U91847
  p38 MAP kinase 2                          Mapk14         U73142
  Protein kinase C, alpha                   Prkca          X07286
  Protein kinase C, zeta                    Prkcz          M18332
  Plasminogen activator, urokinase          Plau           X63434
  VEGF receptor 2                           Kdr            U93306
Ribosomal protein genes
  Ribosomal protein S5                      Rps5           X58465
  Ribosomal protein S4                      Rps4           X14210
  Ribosomal protein S6                      Rps6           M29358
  Ribosomal protein S9                      Rps9           X66370
  Ribosomal protein S8                      Rps8           X06423
  Ribosomal protein S7                      Rps7           X53377
  Ribosomal protein S3                      Rps3           X51536
  40 kDa ribosomal protein                  Lamr1          D25224
  v-fos transformation effector             Rps3a          M84716
  Ribosomal protein L3                      Rpl3           X62166
  Ribosomal protein L5                      Rpl5           M17419
  Ribosomal protein L9                      Rpl9           X51706
  Ribosomal protein L10                     Rpl10          X93352
  Ribosomal protein L11                     Rpl11          X62146
  Ribosomal protein L12                     Rpl12          X53504
  Ribosomal protein L14                     Rpl14          X94242
  Ribosomal protein L17                     Rpl17          X58389
  Ribosomal protein S25                     Rps25          X62482
  Ribosomal protein L7                      Rpl7a          X15013
  Ribosomal protein L18                     Rpl18a         X14181
  Ribosomal protein L21                     Rpl21          M27905
  Ribosomal protein L22                     Rpl22          X60212
  Ribosomal protein L23                     Rpl23          X65228
  Ribosomal protein L26                     Rpl26          X14671
  Ribosomal protein L28                     Rpl28          X52619
  Ribosomal protein L37                     Rpl37          X66369

Gene group/names (a)

                                          Nal       PB       PTU

Wnt signaling genes
  APC fragment 2 of 6                    -- (d)    -1.6      -- (d)
  APC fragment 4 of 6                    --        -2.2     -2.6
  APC protein                            --         --      -2.0
  c-jun oncogene                         --         2.9      2.3
  Cyclin D1                              --         1.4      2.6
  Cyclin 01 partial                      --         1.3      2.3
  Cyclin 03                              --         1.4      1.7
  Cyclin 03 partial                      --         1.6      1.7
  Frizzled homolog 1                     1.5        --       --
  DNA damage inducible transcript        --        -1.7     -2.0
  Insulin-like factor binding protein    --         1.7      5.2
  Low-density lipoprotein receptor       --         --       2.1
  p38 MAP kinase                         --         1.6      --
  p38 MAP kinase 2                       --         --       1.4
  Protein kinase C, alpha                --         --       3.7
  Protein kinase C, zeta                 --         1.6      1.4
  Plasminogen activator, urokinase       --         --      -1.8
  VEGF receptor 2                        --         1.9      2.8
Ribosomal protein genes
Ribosomal protein S5                     --         --      -1.4
  Ribosomal protein S4                   --        -1.4     -1.4
  Ribosomal protein S6                   --        -1.5     -1.2
  Ribosomal protein S9                   --         --      -1.3
  Ribosomal protein S8                   --        -1.3     -1.3
  Ribosomal protein S7                   --         --      -1.3
  Ribosomal protein S3                   --         --      -1.3
  40 kDa ribosomal protein               --         --      -1.3
  v-fos transformation effector          --        -1.6     -1.2
  Ribosomal protein L3                   --         --      -1.4
  Ribosomal protein L5                   --        -1.5      --
  Ribosomal protein L9                   --         --      -1.4
  Ribosomal protein L10                  --         --      -1.4
  Ribosomal protein L11                  --         --      -1.4
  Ribosomal protein L12                  --         --      -1.4
  Ribosomal protein L14                  --         --      -1.3
  Ribosomal protein L17                  --         --      -1.4
  Ribosomal protein S25                  --         --      -1.4
  Ribosomal protein L7                   --         --      -1.3
  Ribosomal protein L18                 -1.4        --       --
  Ribosomal protein L21                  --        -1.4     -1.4
  Ribosomal protein L22                 -2.1        --      -1.8
  Ribosomal protein L23                  --         --      -1.5
  Ribosomal protein L26                  --         --      -1.4
  Ribosomal protein L28                  --         --      -1.3
  Ribosomal protein L37                  --         --       --

(a) From GenBank (http://www.ncbi.nlm.nih.gov). (b)--, Gene symbol
not known. (c)-- p [less than or equal to] 0.03 by regularized
t-test. (d)--, Not statistically significant.

Values represent statistically significant (p < 0.01 by regularized
t-test) mean fold change from control (n = 3) for 100 mg/kg/day Nal
and PB and 10 mg/kg/day PTU.